The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments that harness the body’s immune system to fight cancer have transitioned from speculation to offering endless possibilities for drug discovery. Of these treatments, therapeutic monoclonal antibodies are positioned at the forefront of the immunotherapy revolution, and the FDA has approved several of these monoclonal antibodies to treat cancer.
Advances in mass spectrometry instrumentation and sample handling methods have propelled proteomics and extended its utility for both basic biology and early drug development. Changes in protein abundance and post-translational modification state often reflect the activity of a novel therapeutic agent as well as the sensitivity/resistance of a biological system to treatment.
For those who wish to bring a measure of rationality to the western blot data in the literature, loading controls can induce a fair amount of hand wringing. There are some obvious criteria. First, the protein level of the loading control must not be altered by experimental conditions. Second, the molecular weight of the control must be different from the protein of interest. Third, and most importantly, the signal detected for both the loading control and the protein of interest must be in a linear range, otherwise you’ll find yourself with burnt-out bands that you’ll be unable to quantify.
Topics: Western Blot
It's Pi Day! 3.14! π! We've celebrated before, but this year we wanted to do something bigger. Don't get me wrong, we love baking and eating delicious pies, but have we waxed mathematical!? Well this year, CST's bravest of the brave ran our gauntlet of pi-related trivia! They didn't just eat pie, they earned it. Luckily, CST News anchor Jak Stat and the CST News team were live on the scene.
Topics: Just for fun
As a development scientist at CST, people sometimes ask me what exactly it is that I do. “I make antibodies,” is my typical reply, but that is not exactly true.
Topics: Antibody Validation
Let’s face it, we are an energy-intensive industry. From ultra low temperature freezers for storing products, to HVAC and lighting, plus lab equipment and fume hoods, it all adds up to a significant load. In 2017, CST’s two U.S. facilities used 7,677,140 kWh, which is the equivalent to the electrical consumption of 856 households! While creating that amount of energy on our own would require a golf course sized array of renewables, we can take steps to whittle down a percentage of energy consumption with solar panels on our roof.
Topics: Corporate Social Responsibility
Congratulations to our CEO and founder Dr. Michael J. Comb, whom CiteAb has selected for a lifetime achievement award. Dr. Comb likes fly-fishing in Alaska and rock climbing in Yosemite more than he likes the spotlight, but this award has given us the opportunity to acknowledge our fearless leader. CiteAb recognizes individuals from the research community for their dedication and contribution to the research reagent industry over a sustained period. Dr. Comb is being honored for his tireless efforts to build the best antibody technology in the world for researchers working to understand the molecular and cellular processes of disease.
Topics: Science Education
It’s Valentine’s Day. You can’t put out that bowl of candy hearts because…NO FOOD IN THE LAB!!! Okay, fair enough, but there has to be another way to send a message to someone special at the bench. Why not use antibodies to your advantage? The label of your vials might have all the messaging you need!
Topics: Just for fun
We as scientists learn from each success and failure. Sometimes it takes many failures to achieve success. And some discoveries are made with no fanfare, far from the spotlight. Other times, a good day’s work is even sweeter when you realize someone noticed!
So your experiments and data are funneling you down an inescapable path. You need to show direct gene regulation by your protein of interest. You think to yourself, “Oh, ChIP...”